» Articles » PMID: 11907110

Depletion of CD8+ T Cells Exacerbates CD4+ Th Cell-associated Inflammatory Lesions During Murine Mycoplasma Respiratory Disease

Overview
Journal J Immunol
Date 2002 Mar 22
PMID 11907110
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Mycoplasma infection is a leading cause of pneumonia worldwide and can lead to other respiratory complications. A component of mycoplasma respiratory diseases is immunopathologic, suggesting that lymphocyte activation is a key event in the progression of these chronic inflammatory diseases. The present study delineates the changes in T cell populations and their activation after mycoplasma infection and determines their association with the pathogenesis of murine Mycoplasma respiratory disease, due to Mycoplasma pulmonis infection. Increases in T cell population numbers in lungs and lower respiratory lymph nodes were associated with the development of mycoplasma respiratory disease. Although both pulmonary Th and CD8(+) T cells increased after mycoplasma infection, there was a preferential expansion of Th cells. Mycoplasma-specific Th2 responses were dominant in lower respiratory lymph nodes, while Th1 responses predominated in spleen. However, both mycoplasma-specific Th1 and Th2 cytokine (IL-4 and IFN-gamma) responses were present in the lungs, with Th1 cell activation as a major component of the pulmonary Th cell response. Although a smaller component of the T cell response, mycoplasma-specific CD8(+) T cells were also a significant component of pulmonary lymphoid responses. In vivo depletion of CD8(+) T cells resulted in dramatically more severe pulmonary disease, while depletion of CD4(+) T cells reduced its severity, but there was no change in mycoplasma numbers in lungs after cell depletion. Thus, mycoplasma-specific Th1 and CD8(+) T cell activation in the lung plays a critical regulatory role in development of immunopathologic reactions in Mycoplasma respiratory disease.

Citing Articles

Predictive value of immune-related parameters in severe pneumonia in children.

Jiang C, Bao S, Shen W, Wang C Transl Pediatr. 2024; 13(9):1521-1528.

PMID: 39399713 PMC: 11467233. DOI: 10.21037/tp-24-172.


A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC Study.

Meyer Sauteur P, Seiler M, Tilen R, Osuna E, von Wantoch M, Sidorov S Trials. 2024; 25(1):655.

PMID: 39363201 PMC: 11450998. DOI: 10.1186/s13063-024-08438-6.


Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children.

Fan F, Lv J, Yang Q, Jiang F Clin Respir J. 2023; 17(7):607-617.

PMID: 37142438 PMC: 10363789. DOI: 10.1111/crj.13620.


Pneumocystis Pneumonia With Multiple Centrilobular Pulmonary Nodules and Lack of Ground-Glass Attenuation on High-Resolution Computed Tomography.

Takaki R, Komiya K, Fujishima N, Yamanaka M, Yokoyama A, Hiramatsu K Cureus. 2023; 15(2):e35565.

PMID: 37007317 PMC: 10061157. DOI: 10.7759/cureus.35565.


Different local, innate and adaptive immune responses are induced by two commercial bacterins and an adjuvant alone.

Beuckelaere L, Haspeslagh M, Biebaut E, Boyen F, Haesebrouck F, Krejci R Front Immunol. 2022; 13:1015525.

PMID: 36569943 PMC: 9768447. DOI: 10.3389/fimmu.2022.1015525.